The Therapeutics Goods Administration (TGA) has extended the approval of the RSV vaccine Arexvy to include adults aged 50 to 59 years who are at increased risk for RSV disease.
Arexvy is also approved for use in all adults aged 60 years and older.
For more information on RSV disease and vaccination, see MVEC’s updated RSV immunisation reference.